A Leading Pharmaceutical Brand Increased Adherence 29% YoY with Swoop’s Patented Predictive Non-Adherence Audiences
With an increased incidence in substance use disorders (SUDs), a MAT therapy wanted to increase adherence within its patient population to drive positive patient outcomes. Leveraging Swoop’s patented predictive technology, the brand was able to accurately identify patients most likely to become non-adherent and activate them programmatically across premium inventory.
Help patients start and stay on therapy programs prescribed by their doctors
NimbleRx, a Swoop Company, connects prescription fulfillment capabilities with commercial intelligence to turn real-world signals into action, improve medication adherence, and reduce treatment delays.
Swoop and Bayer explain how brands can think differently about their targeting strategies to optimize engagement, improve patient outcomes, and drive Rx lift.
Kurt Robinson, Senior Vice President of Business Development for Swoop, spoke with Marc Iskowitz, editor-at-large of MM+M to discuss how custom audiences are transforming TV advertising for the life sciences industry.
Erin Deruggiero, Chief Digital Officer at Swoop, sat down with Marc Iskowitz, Editor in Chief of MM+M to discuss the increased benefits to both marketers and patients when campaigns align.